NCT05677503

Brief Summary

the study is to investigate the relationship of several parameters of complete blood count (CBC) including RDW with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) in a cohort of acute myocardial infarction (AMI) patients.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2023

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 23, 2022

Completed
18 days until next milestone

First Posted

Study publicly available on registry

January 10, 2023

Completed
5 days until next milestone

Study Start

First participant enrolled

January 15, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2023

Completed
Last Updated

January 12, 2023

Status Verified

January 1, 2023

Enrollment Period

6 months

First QC Date

December 23, 2022

Last Update Submit

January 11, 2023

Conditions

Myocardial Infarction

Outcome Measures

Primary Outcomes (3)

  • complete blood count (CBC)

    measurement of CBC levels will be performed

    7 months

  • Level of (NT-proBNP)

    measurement of serum NT-proBNP level will be performed

    7 months

  • Level of (cTnT)

    measurement of cTnT level will be performed

    7 months

Interventions

CBCDIAGNOSTIC_TEST

measurement of CBC will be performed at the time of admission and by the time of discharge

(NT-proBNP)DIAGNOSTIC_TEST

measurement of serum NT-proBNP levels will be performed at the time of admission and by the time of discharge

(cTnT)DIAGNOSTIC_TEST

measurement of cTnT levels will be performed at the time of admission and by the time of discharge

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

\_All patients included in the study will be subjected to: 1. Full history: 1. Personal history: e.g. age, sex and smoking. 2. Family history of cardiac diseases 3. Medical history of: Hypertension, Ischemic heart disease, prior coronary artery bypass grafting, Prior Percutaneous coronary intervention, Prior Stroke, Prior Atrial fibrillation, therapeutic history 2. Detailed clinical examination 3. Electrocardiogram 4. Laboratory investigation: 1. Routine investigation in the form of CBC including RDW 2. Specific investigation which include NT-proBNP and cTnT

You may qualify if:

  • patients diagnosed as acute myocardial infarction

You may not qualify if:

  • Patient with
  • Decompensated heart failure
  • Pulmonary hypertention
  • Acute pulmonary embolism
  • Septic shock

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor at clinical and chemical pathology department

Study Record Dates

First Submitted

December 23, 2022

First Posted

January 10, 2023

Study Start

January 15, 2023

Primary Completion

June 30, 2023

Study Completion

July 30, 2023

Last Updated

January 12, 2023

Record last verified: 2023-01